A Phase 4 interventional study of Macitentan in Pulmonary Arterial Hypertension, sponsored by Actelion. Completed at 41 sites in 12 countries. Open to participants aged 18 Years to 64 Years. Per ClinicalTrials.gov, last updated 2025-03-30.
Sponsored by Actelion (part of Johnson & Johnson) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies testing macitentan in Pulmonary Arterial Hypertension — 1 open to participants now, 2 under way, 2 of them phase 3. macitentan · Pulmonary Arterial Hypertension.
Among the 18 studies testing macitentan in Pulmonary Arterial Hypertension, this one is the 11th largest by enrollment, is one of 3 that started in 2015, is one of 2 in phase 4, and was the 9th registered.
701 studies on the registry are indexed under Pulmonary Arterial Hypertension; 142 are open to participants now.
Browse Pulmonary Arterial Hypertension studies →1 of the 18 studies testing macitentan in Pulmonary Arterial Hypertension is open now, in 12 countries. Recruiting first, the newest first:
Actelion · Sites in Belarus, Belgium, Bulgaria and 10 more countries
Ages 2+
By country, each count listing its studies:
macitentan: first FDA approval 2013 (OPSUMIT), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →
Of the 90 Pulmonary Arterial Hypertension studies recruiting now, 51 (57%) set no upper age limit and 24 (27%) stop at 75 or younger; 18 take children under 18; 11 take healthy volunteers.
This study: 18 Years to 64 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 3 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 89 is above the median of 40 across 478 interventional studies indexed under Pulmonary Arterial Hypertension.
Median enrollment 156 across the 18 interventional studies. Of the 15 that completed or were terminated, 11 (73%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 18 have an industry lead sponsor. The 4 most frequent:
This study is registered under Actelion, one of the names counted as Johnson & Johnson. Under that name alone:
Actelion is the lead sponsor of 143 studies on the registry; 1 is open to participants now.
Of its 28 completed or terminated interventional studies of FDA-regulated products, 25 (89%) have results posted.
63 studies in Pulmonary Arterial Hypertension by Johnson & Johnson: 2 open now, 5 under way, 2 of them phase 3. Of 55 finished, 33 (60%) have results posted.
Among the 63 studies in Pulmonary Arterial Hypertension by Johnson & Johnson, this one is the 20th largest by enrollment of the 51 interventional ones that give a count, is one of 4 that started in 2015, is one of 11 in phase 4, and was the 42nd registered.
Johnson & Johnson’s Pulmonary Arterial Hypertension studies by the year they started, since 2003.
1 of the studies testing macitentan in Pulmonary Arterial Hypertension that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05179876Phase 3ActelionA Study Providing Treatment Access in Participants With Pulmonary Hypertension Completing a Parent Study and Having no Other Option | 2027-01-31 |
Add it to your calendar (.ics) → With an account.
Among the 18 studies testing macitentan in Pulmonary Arterial Hypertension, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Johnson & Johnson’s 63 in Pulmonary Arterial Hypertension:
This tab as a report to print or save as PDF → With an account.
The study evaluates the effect of macitentan on right ventricular and hemodynamic properties in patients with symptomatic pulmonary arterial hypertension. Patients are treated with macitentan for 1 year. Patients undergo right heart catheterization (RHC) at baseline and Week 26. They also undergo cardiac magnetic resonance imaging (MRI) at baseline, Week 26 and Week 52. Safety is monitored throughout the study. The study has three stub-studies. Each patient can participate in no sub-study or in one sub-study. The sub-studies are: (1) metabolism sub-study (with PET-MR scans); (2) biopsy sub-study (biopsies taken during the RHC); (3) Echo sub-study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
PAH etiology belonging to one of the following groups according to Nice classification:
Hemodynamic diagnosis of PAH confirmed by right heart catheterization (RHC) during screening showing:
Women of (defined in protocol) must:
Exclusion Criteria:
Historical evidence of significant coronary artery disease established by:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
All patients take open-label macitentan 10mg o.d.
Drug: Macitentan
All patients take open-label macitentan 10mg o.d.
Also known as: ACT-064992
Change From Baseline in Right Ventricular Stroke Volume (RVSV) to Week 26
Change from baseline in RVSV assessed by cardiac magnetic resonance imaging (MRI) from pulmonary artery flow was reported at Week 26. Primary analysis were based on interim results as pre-planned and the primary outcome measures data table reported is finalized as is.
Time frame: Baseline and Week 26
Ratio of Week 26 to Baseline Pulmonary Vascular Resistance (PVR)
Ratio of Week 26 to baseline PVR as assessed by RHC was reported. PVR represents the resistance against which the right ventricle needs to pump. PVR is determined by right heart catheterization (RHC). PVR was calculated as 80\*(Mean pulmonary arterial pressure \[mPAP\] -\[Pulmonary capillary wedge pressure {PCWP} or Left ventricular end diastolic pressure {LVEDP} if PCWP not available/cardiac output \[CO\]). Primary analysis were based on interim results as pre-planned and the primary outcome measures data table reported is finalized as is.
Time frame: Baseline and Week 26
Change From Baseline in Right Ventricular End Diastolic Volume (RVEDV) to Week 26
Change from baseline to Week 26 in RVEDV assessed by cardiac MRI was reported.
Time frame: Baseline to Week 26
Change From Baseline in Right Ventricular End Systolic Volume (RVESV) to Week 26
Change from baseline to Week 26 in RVESV assessed by cardiac MRI was reported.
Time frame: Baseline to Week 26
Change From Baseline in Right Ventricular Ejection Fraction (RVEF) to Week 26 (% Blood Volume)
Change from baseline to Week 26 in RVEF based on pulmonary artery flow assessed by cardiac MRI was reported.
Time frame: Baseline to Week 26
Change From Baseline in Right Ventricle (RV) Mass to Week 26
Change from baseline to Week 26 in RV mass assessed by cardiac MRI was reported.
Time frame: Baseline to Week 26
Change From Baseline in Six-minutes Walk Distance (6MWD) to Week 26
6MWD is a non-encouraged test performed in a 30 meter (m) long flat corridor, where the participant is instructed to walk as far as possible, back and forth around two cones, with the permission to slow down, rest, or stop if needed. This test is used to assess exercise capacity. The test was performed about 30 minutes after study drug administration. Any increase in the walk distance was considered improvement from baseline.
Time frame: Baseline to Week 26
Change From Baseline in World Health Organization Functional Class (WHO FC) to Week 26
WHO FC is a classification which reflects disease severity based on symptoms. WHO Functional Classification of pulmonary hypertension comprises of Class I (participants with pulmonary hypertension but without resulting limitation of physical activity), II (participants with pulmonary hypertension resulting in slight limitation of physical activity), III (participants with pulmonary hypertension resulting in marked limitation of physical activity) and IV (participants with pulmonary hypertension with inability to carry out any physical activity without symptoms). Changes from baseline to Week 26 included: improvement (change from a higher to a lower FC), worsening (change from a lower to a higher FC) or unchanged/stable (same FC at baseline and at the post-baseline time point).
Time frame: Baseline to Week 26
| Milestone | Macitentan 10 mg |
|---|---|
| Started | 87 |
| Completed | 72 |
| Not completed | 15 |
| Withdrew: Death | 1 |
| Withdrew: Lost to follow-up | 1 |
| Withdrew: Withdrawal by subject | 1 |
| Withdrew: Sponsor's decision | 12 |
Change from baseline in RVSV assessed by cardiac magnetic resonance imaging (MRI) from pulmonary artery flow was reported at Week 26. Primary analysis were based on interim results as pre-planned and the primary outcome measures data table reported is finalized as is.
| milliliters (mL) | Macitanten 10 mg |
|---|---|
| Change From Baseline in Right Ventricular Stroke Volume (RVSV) to Week 26 | 15.17 ± 2.75 |
Ratio of Week 26 to baseline PVR as assessed by RHC was reported. PVR represents the resistance against which the right ventricle needs to pump. PVR is determined by right heart catheterization (RHC). PVR was calculated as 80\*(Mean pulmonary arterial pressure \[mPAP\] -\[Pulmonary capillary wedge pressure {PCWP} or Left ventricular end diastolic pressure {LVEDP} if PCWP not available/cardiac output \[CO\]). Primary analysis were based on interim results as pre-planned and the primary outcome measures data table reported is finalized as is.
| Ratio | Macitanten 10 mg |
|---|---|
| Ratio of Week 26 to Baseline Pulmonary Vascular Resistance (PVR) | 0.63 ± 0.11 |
Change from baseline to Week 26 in RVEDV assessed by cardiac MRI was reported.
| mL | Macitanten 10 mg |
|---|---|
| Change From Baseline in Right Ventricular End Diastolic Volume (RVEDV) to Week 26 | -6.22 (-12.50 to 0.07) |
Change from baseline to Week 26 in RVESV assessed by cardiac MRI was reported.
| mL | Macitanten 10 mg |
|---|---|
| Change From Baseline in Right Ventricular End Systolic Volume (RVESV) to Week 26 | -16.39 (-20.56 to -12.21) |
Change from baseline to Week 26 in RVEF based on pulmonary artery flow assessed by cardiac MRI was reported.
| Percentage of blood volume | Macitanten 10 mg |
|---|---|
| Change From Baseline in Right Ventricular Ejection Fraction (RVEF) to Week 26 (% Blood Volume) | 10.14 (7.46 to 12.83) |
Change from baseline to Week 26 in RV mass assessed by cardiac MRI was reported.
| Grams | Macitanten 10 mg |
|---|---|
| Change From Baseline in Right Ventricle (RV) Mass to Week 26 | -10.10 (-13.81 to -6.39) |
6MWD is a non-encouraged test performed in a 30 meter (m) long flat corridor, where the participant is instructed to walk as far as possible, back and forth around two cones, with the permission to slow down, rest, or stop if needed. This test is used to assess exercise capacity. The test was performed about 30 minutes after study drug administration. Any increase in the walk distance was considered improvement from baseline.
| Meters | Macitanten 10 mg |
|---|---|
| Change From Baseline in Six-minutes Walk Distance (6MWD) to Week 26 | 38.85 ± 7.37 |
WHO FC is a classification which reflects disease severity based on symptoms. WHO Functional Classification of pulmonary hypertension comprises of Class I (participants with pulmonary hypertension but without resulting limitation of physical activity), II (participants with pulmonary hypertension resulting in slight limitation of physical activity), III (participants with pulmonary hypertension resulting in marked limitation of physical activity) and IV (participants with pulmonary hypertension with inability to carry out any physical activity without symptoms). Changes from baseline to Week 26 included: improvement (change from a higher to a lower FC), worsening (change from a lower to a higher FC) or unchanged/stable (same FC at baseline and at the post-baseline time point).
| Participants | Macitanten 10 mg |
|---|---|
| Missing WHO FC | 5 |
| Worsened WHO FC | 1 |
| Unchanged WHO FC | 35 |
| Improved WHO FC | 46 |
Collected over Up to 420 Days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Macitentan 10 mg | 1/87 (1.1%) | 15/87 (17.2%) | 57/87 (65.5%) |
| Event | Macitentan 10 mg |
|---|---|
| PneumoniaInfections and infestations | 3/87 |
| Acute Myocardial InfarctionCardiac disorders | 2/87 |
| SepsisInfections and infestations | 2/87 |
| Pulmonary Arterial HypertensionRespiratory, thoracic and mediastinal disorders | 2/87 |
| Pulmonary EmbolismRespiratory, thoracic and mediastinal disorders | 2/87 |
| AnaemiaBlood and lymphatic system disorders | 1/87 |
| Haemolytic AnaemiaBlood and lymphatic system disorders | 1/87 |
| Iron Deficiency AnaemiaBlood and lymphatic system disorders | 1/87 |
| Angina PectorisCardiac disorders | 1/87 |
| Atrial FibrillationCardiac disorders | 1/87 |
| Event | Macitentan 10 mg |
|---|---|
| Oedema PeripheralGeneral disorders | 19/87 |
| HeadacheNervous system disorders | 18/87 |
| DizzinessNervous system disorders | 12/87 |
| Upper Respiratory Tract InfectionInfections and infestations | 10/87 |
| Haemoglobin DecreasedInvestigations | 10/87 |
| CoughRespiratory, thoracic and mediastinal disorders | 10/87 |
| MyalgiaMusculoskeletal and connective tissue disorders | 9/87 |
| DiarrhoeaGastrointestinal disorders | 8/87 |
| Nasal CongestionRespiratory, thoracic and mediastinal disorders | 8/87 |
| PyrexiaGeneral disorders | 7/87 |
Safety Set included all screened participants who received at least one dose of study drug.
| Age, Continuous(years) | Macitentan 10 mg |
|---|---|
| Mean | 45.9 ± 14.48 |
| Sex: Female, Male(Participants) | Macitentan 10 mg |
|---|---|
| Female | 70 |
| Male | 17 |
| Ethnicity (NIH/OMB)(Participants) | Macitentan 10 mg |
|---|---|
| Hispanic or Latino | 1 |
| Not Hispanic or Latino | 72 |
| Unknown or Not Reported | 14 |
| Race/Ethnicity, Customized(Participants) | Macitentan 10 mg |
|---|---|
| Black or African American | 1 |
| American Indian or Alaska Native | 0 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Asian | 26 |
| White | 46 |
| Other | 0 |
| Unknown or Not Reported | 14 |
| Region of Enrollment(Participants) | Macitentan 10 mg |
|---|---|
| FRANCE | 14 |
| GERMANY | 12 |
| ISRAEL | 2 |
| ITALY | 3 |
| MALAYSIA | 8 |
| NETHERLANDS | 12 |
| RUSSIAN FEDERATION | 11 |
| SINGAPORE | 9 |
| UNITED KINGDOM | 3 |
| UNITED STATES | 6 |
| Hong Kong | 7 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jun 2015 to primary completion in Sep 2019, 51 months.
Results were first posted in Sep 2020, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Macitentan
Pulmonary Arterial Hypertension →